Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the beleaguered Somerville-based biotech avoid bankruptcy.
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...
The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...
BofA moved to No Rating on Bluebird Bio (BLUE) after the company announced it has entered a definitive merger agreement under which Carlyle and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback